These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31349931)

  • 1. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
    Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
    Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Valera E; Masliah E
    Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
    Rodger AT; ALNasser M; Carter WG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The good and bad of therapeutic strategies that directly target α-synuclein.
    Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
    IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.
    Vargas JY; Grudina C; Zurzolo C
    Ageing Res Rev; 2019 Mar; 50():89-101. PubMed ID: 30690184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
    Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
    PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
    Wang Z; Gao G; Duan C; Yang H
    Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease.
    He S; Zhong S; Liu G; Yang J
    Neurodegener Dis; 2020; 20(2-3):55-64. PubMed ID: 33465773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
    Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
    J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.